Salmeterol free base
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522405

CAS#: 18910-65-1 (free base)

Description: Salmeterol is a long-acting beta2-adrenergic receptor agonist drug used in the maintenance and prevention of asthma symptoms and maintenance of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms include shortness of breath, wheezing, coughing and chest tightness. Salmeterol is also used to prevent breathing difficulties during exercise (exercise induced bronchospasm). It is marketed as Serevent in the US.


Chemical Structure

img
Salmeterol free base
CAS# 18910-65-1 (free base)

Theoretical Analysis

MedKoo Cat#: 522405
Name: Salmeterol free base
CAS#: 18910-65-1 (free base)
Chemical Formula: C25H37NO4
Exact Mass: 415.2723
Molecular Weight: 415.574
Elemental Analysis: C, 72.26; H, 8.97; N, 3.37; O, 15.40

Price and Availability

Size Price Availability Quantity
10.0mg USD 335.0 2 Weeks
50.0mg USD 950.0 2 Weeks
Bulk inquiry

Related CAS #: 18910-65-1 (free base)   94749-08-3 (xinafoate)    

Synonym: Salmeterol free base; Astmerole; GR 33343 X; GR 33343X; GR33343X; GR-33343X; SN408D.

IUPAC/Chemical Name: 4-Hydroxy-alpha1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol

InChi Key: GIIZNNXWQWCKIB-UHFFFAOYSA-N

InChi Code: InChI=1S/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2

SMILES Code: OC(CNCCCCCCOCCCCC1=CC=CC=C1)C2=CC=C(O)C(CO)=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 415.574 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Liu S, Watts AB, Du J, Bui A, Hengsawas S, Williams RO 3rd. Formulation of a novel fixed dose combination of salmeterol xinafoate and mometasone furoate for inhaled drug delivery. Eur J Pharm Biopharm. 2015 Jul 26. pii: S0939-6411(15)00317-3. doi: 10.1016/j.ejpb.2015.07.017. [Epub ahead of print] PubMed PMID: 26220015.

2: Anwar MM, El-Haggar RS, Zaghary WA. Salmeterol Xinafoate. Profiles Drug Subst Excip Relat Methodol. 2015;40:321-69. doi: 10.1016/bs.podrm.2015.02.002. Epub 2015 Apr 1. Review. PubMed PMID: 26051688.

3: Hassoun M, Ho S, Muddle J, Buttini F, Parry M, Hammond M, Forbes B. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers. Int J Pharm. 2015 Jul 25;490(1-2):360-7. doi: 10.1016/j.ijpharm.2015.05.028. Epub 2015 May 15. PubMed PMID: 25987210.

4: Bi S, Wang T, Wang Y, Zhao T, Zhou H. Using gold nanoparticles as probe for detection of salmeterol xinafoate by resonance Rayleigh light scattering. Spectrochim Acta A Mol Biomol Spectrosc. 2015 Jan 25;135:1074-9. doi: 10.1016/j.saa.2014.08.010. Epub 2014 Aug 19. PubMed PMID: 25173524.

5: Zhao T, Bi S, Wang Y, Wang T, Pang B, Gu T. In vitro studies on the behavior of salmeterol xinafoate and its interaction with calf thymus DNA by multi-spectroscopic techniques. Spectrochim Acta A Mol Biomol Spectrosc. 2014 Nov 11;132:198-204. doi: 10.1016/j.saa.2014.04.158. Epub 2014 May 9. PubMed PMID: 24866086.

6: Restrepo RD, Tate A, Coquat J. Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013 Oct;14(14):1993-2002. doi: 10.1517/14656566.2013.823949. Epub 2013 Jul 31. Review. PubMed PMID: 23898819.

7: Dalal AA, Candrilli SD, Davis KL. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD. Manag Care. 2011 Aug;20(8):46-50, 53-5. PubMed PMID: 21887993.

8: Harrison LI, Novak CC, Needham MJ, Ratner P. Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma. J Aerosol Med Pulm Drug Deliv. 2011 Oct;24(5):245-52. doi: 10.1089/jamp.2011.0884. Epub 2011 Jun 14. PubMed PMID: 21671752.

9: Kasaye L, Hymete A, Mohamed AM. HPTLC-densitometric method for simultaneous determination of salmeterol xinafoate and fluticasone propionate in dry powder inhalers. Saudi Pharm J. 2010 Jul;18(3):153-9. doi: 10.1016/j.jsps.2010.05.001. Epub 2010 May 31. PubMed PMID: 23964174; PubMed Central PMCID: PMC3731032.

10: Mostafapour E, Mousavi SA, Shahmiri SS, Fereshtehnejad SM. Effects of combination of fluticasone propionate and salmeterol xinafoate on lung function improvement in patients with bronchiectasis. Lijec Vjesn. 2009 Nov;131 Suppl 6:8-11. PubMed PMID: 22046624.



Additional Information

Related CAS#
CAS#94749-08-3 (Salmeterol xinafoate salt)
CAS#89365-50-4 (Salmeterol free base).